


UPDATED CDC recommendations

All eligible adults aged **50+** are recommended for pneumococcal vaccination¹⁻³



The CDC recommends Prevnar 20® for ALL of the following eligible adult patients¹⁻³:

Eligible adults	Previous vaccination history			
	Pneumococcal vaccination-naïve* or unknown	PCV13 only (≥1 year prior)	PPSV23 only (≥1 year prior)	PCV13 and PPSV23 (≥5 years prior)
≥50	✓	✓	✓	✓ [†]
19-49 with certain underlying medical conditions or other risk factors [†]	✓	✓	✓	Review schedule when patient turns 50
19-49 with specified immunocompromising conditions, cochlear implant, or CSF leak	✓	✓	✓	✓ [§]

See ACIP recommendations for a full set of pneumococcal adult recommendations.

ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention; CHF=congestive heart failure; COPD=chronic obstructive pulmonary disease; CSF=cerebrospinal fluid; HIV=human immunodeficiency virus; PCV7=7-valent pneumococcal conjugate vaccine; PCV13=13-valent pneumococcal conjugate vaccine; PCV15=15-valent pneumococcal conjugate vaccine; PCV20=20-valent pneumococcal conjugate vaccine; PPSV23=23-valent pneumococcal polysaccharide vaccine.

*Also applies to people who received PCV7 at any age and have received no other pneumococcal vaccines.²

[†]If PCV13 was administered at any age and PPSV23 was administered before age 65 with the last pneumococcal vaccine being at least 5 years prior, then the patient is eligible for Prevnar 20 as part of a routine vaccination. Based on shared clinical decision-making, a patient is eligible to receive Prevnar 20 if PCV13 (but not PCV15, PCV20, or PCV21) was administered at any age, PPSV23 was administered at or after the age of 65, and the last pneumococcal vaccine was at least 5 years prior.²

[‡]Adults with chronic medical conditions were previously not recommended to receive PCV13, and there is no current CDC recommendation for those who have received both PCV13 and PPSV23.²

[§]Also applies to those with an immunocompromising condition (listed below) who have received PCV13 plus 2 doses of PPSV23.²

Underlying medical conditions or other risk factors

Alcoholism; chronic heart disease (including CHF and cardiomyopathies); chronic liver disease; chronic lung disease (including COPD, emphysema, and asthma); chronic renal failure¹; cigarette smoking; cochlear implant; congenital or acquired asplenia¹; cerebrospinal fluid leak; diabetes; generalized malignancy¹; HIV infection¹; Hodgkin disease¹; congenital or acquired immunodeficiency (includes B- [humoral] or T-lymphocyte deficiency, complement deficiencies [particularly C1, C2, C3, and C4 deficiencies], and phagocytic disorders [excluding chronic granulomatous disease])¹; iatrogenic immunosuppression (diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy)¹; leukemia¹; lymphoma¹; multiple myeloma¹; nephrotic syndrome¹; solid organ transplant¹; sickle cell disease or other hemoglobinopathies^{1,2,4}

¹Immunocompromising conditions.^{2,4}

INDICATION


- Prevnar 20® is a vaccine indicated for:
 - active immunization for the prevention of invasive disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
 - active immunization for the prevention of pneumonia caused by *S. pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older
- The indication for the prevention of pneumonia caused by *S. pneumoniae* serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in individuals 18 years of age and older is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial

IMPORTANT SAFETY INFORMATION

- Do not administer Prevnar 20® to individuals with severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or to diphtheria toxoid

Please see Indication above and Important Safety Information throughout, and see Full Prescribing Information for Prevnar 20®.

Pevnar 20[®] helps protect a broad population of at-risk adults, CDC recommended for eligible adults aged 50+^{1,2}



1 DOSE AND DONE

Pevnar 20 helps protect all **eligible adult patients against pneumococcal pneumonia and IPD^{1,2*}**:

- **Aged 50 or older**
- Adults aged 19-49 with certain underlying medical conditions[†] like **diabetes, asthma, COPD, or chronic heart disease**

One dose of Pevnar 20 completes the CDC recommendation for adult pneumococcal protection¹⁻³

Expand your discussion of Pevnar 20 to all eligible patients aged 50+^{1,2}



Pevnar 20 is covered by both commercial and public health plans across the full CDC recommendation.

Learn more about cost and coverage for your aged **50+** adult patients; click the **[Pevnar 20 Cost & Coverage](#)** calculator or scan the QR code.

CDC=Centers for Disease Control and Prevention; CHF=congestive heart failure; COPD=chronic obstructive pulmonary disease; HIV=human immunodeficiency virus; IPD=invasive pneumococcal disease; QR=quick response.

*Only one dose of Pevnar 20 is required for eligible adult patients per the CDC recommendation.³

[†]Alcoholism; chronic heart disease (including CHF and cardiomyopathies); chronic liver disease; chronic lung disease (including COPD, emphysema, and asthma); chronic renal failure[‡]; cigarette smoking; cochlear implant; congenital or acquired asplenia[‡]; cerebrospinal fluid leak; diabetes; generalized malignancy[‡]; HIV infection[‡]; Hodgkin disease[‡]; congenital or acquired immunodeficiency (includes B- [humoral] or T-lymphocyte deficiency, complement deficiencies [particularly C1, C2, C3, and C4 deficiencies], and phagocytic disorders [excluding chronic granulomatous disease])[‡]; iatrogenic immunosuppression (diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy)[‡]; leukemia[‡]; lymphoma[‡]; multiple myeloma[‡]; nephrotic syndrome[‡]; solid organ transplant[‡]; sickle cell disease or other hemoglobinopathies^{‡,4}

[‡]Immunocompromising conditions.^{2,4}



Manufactured by Wyeth Pharmaceuticals LLC.

Marketed by Pfizer Inc.

PP-PNR-USA-2644-02 © 2024 Pfizer Inc. All rights reserved. November 2024

IMPORTANT SAFETY INFORMATION

- Safety and immunogenicity data on Pevnar 20[®] are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Pevnar 20[®]
- In individuals 18 years of age and older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in individuals 18 through 59 years of age

References: 1. Pevnar 20[®] (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information. Wyeth Pharmaceuticals LLC, 2023. **2.** Centers for Disease Control and Prevention. Pneumococcal vaccine timing for adults. October 26, 2024. Accessed November 1, 2024. <https://www.cdc.gov/pneumococcal/downloads/Vaccine-Timing-Adults-JobAid.pdf> **3.** Kobayashi M. Summary of Work Group interpretation of EtR and policy options: PCV use in adults aged ≥50 years. Presented at: Advisory Committee on Immunization Practices; October 23, 2024; Atlanta, GA. Accessed October 23, 2024. <https://www.cdc.gov/acip/downloads/slides-2024-10-23-24/04-Kobayashi-Pneumococcal-508.pdf> **4.** Kobayashi M, Leidner AJ, Gierke R, et al. Use of 21-valent pneumococcal conjugate vaccine among U.S. adults: recommendations of the Advisory Committee on Immunization Practices — United States, 2024. *MMWR Morb Mortal Wkly Rep.* 2024;73(36):793–798.

Please see Indication above and Important Safety Information throughout, and see [Full Prescribing Information for Pevnar 20[®]](#).